201 related articles for article (PubMed ID: 33734864)
21. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS; Lerebours F; Ciruelos E; Drullinsky P; Ruiz-Borrego M; Neven P; Park YH; Prat A; Bachelot T; Juric D; Turner N; Sophos N; Zarate JP; Arce C; Shen YM; Turner S; Kanakamedala H; Hsu WC; Chia S
Lancet Oncol; 2021 Apr; 22(4):489-498. PubMed ID: 33794206
[TBL] [Abstract][Full Text] [Related]
22. Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial.
Masuda N; Bando H; Yamanaka T; Kadoya T; Takahashi M; Nagai SE; Ohtani S; Aruga T; Suzuki E; Kikawa Y; Yasojima H; Kasai H; Ishiguro H; Kawabata H; Morita S; Haga H; Kataoka TR; Uozumi R; Ohno S; Toi M
Breast Cancer Res Treat; 2021 Jul; 188(1):117-131. PubMed ID: 33763789
[TBL] [Abstract][Full Text] [Related]
23. Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply.
Burstein HJ
N Engl J Med; 2021 Mar; 384(12):1176-1177. PubMed ID: 33761226
[No Abstract] [Full Text] [Related]
24. Adjuvant endocrine therapy in HER2-positive breast cancer patients: systematic review and meta-analysis.
Peleg Hasson S; Brezis MR; Shachar E; Shachar SS; Wolf I; Sonnenblick A
ESMO Open; 2021 Apr; 6(2):100088. PubMed ID: 33735801
[TBL] [Abstract][Full Text] [Related]
25. Less Is More-Ways to Move Forward for Improved Breast Cancer Risk Stratification.
Tehranifar P; Wei Y; Terry MB
Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):587-589. PubMed ID: 33811169
[TBL] [Abstract][Full Text] [Related]
26. What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
Ando K; Shimomura A; Yoshimura K; Kawamura Y; Shimizu C
J Clin Oncol; 2021 Jun; 39(17):1946-1947. PubMed ID: 33793293
[No Abstract] [Full Text] [Related]
27. Patient-Reported Outcomes in Patients With
Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
[TBL] [Abstract][Full Text] [Related]
28. Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).
Moreno-Aspitia A; Holmes EM; Jackisch C; de Azambuja E; Boyle F; Hillman DW; Korde L; Fumagalli D; Izquierdo MA; McCullough AE; Wolff AC; Pritchard KI; Untch M; Guillaume S; Ewer MS; Shao Z; Sim SH; Aziz Z; Demetriou G; Mehta AO; Andersson M; Toi M; Lang I; Xu B; Smith IE; Barrios CH; Baselga J; Gelber RD; Piccart-Gebhart M;
Eur J Cancer; 2021 May; 148():287-296. PubMed ID: 33765513
[TBL] [Abstract][Full Text] [Related]
29. Tipifarnib in Head and Neck Squamous Cell Carcinoma With
Ho AL; Brana I; Haddad R; Bauman J; Bible K; Oosting S; Wong DJ; Ahn MJ; Boni V; Even C; Fayette J; Flor MJ; Harrington K; Kim SB; Licitra L; Nixon I; Saba NF; Hackenberg S; Specenier P; Worden F; Balsara B; Leoni M; Martell B; Scholz C; Gualberto A
J Clin Oncol; 2021 Jun; 39(17):1856-1864. PubMed ID: 33750196
[TBL] [Abstract][Full Text] [Related]
30. Breast cancer risk and hormone replacement therapy among BRCA carriers after risk-reducing salpingo-oophorectomy.
Michaelson-Cohen R; Gabizon-Peretz S; Armon S; Srebnik-Moshe N; Mor P; Tomer A; Levy-Lahad E; Paluch-Shimon S
Eur J Cancer; 2021 May; 148():95-102. PubMed ID: 33743487
[TBL] [Abstract][Full Text] [Related]
31. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Bardia A; Messersmith WA; Kio EA; Berlin JD; Vahdat L; Masters GA; Moroose R; Santin AD; Kalinsky K; Picozzi V; O'Shaughnessy J; Gray JE; Komiya T; Lang JM; Chang JC; Starodub A; Goldenberg DM; Sharkey RM; Maliakal P; Hong Q; Wegener WA; Goswami T; Ocean AJ
Ann Oncol; 2021 Jun; 32(6):746-756. PubMed ID: 33741442
[TBL] [Abstract][Full Text] [Related]
32. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
McGrail DJ; Pilié PG; Rashid NU; Voorwerk L; Slagter M; Kok M; Jonasch E; Khasraw M; Heimberger AB; Lim B; Ueno NT; Litton JK; Ferrarotto R; Chang JT; Moulder SL; Lin SY
Ann Oncol; 2021 May; 32(5):661-672. PubMed ID: 33736924
[TBL] [Abstract][Full Text] [Related]
33. Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET).
Vernieri C; Nichetti F; Lalli L; Moscetti L; Giorgi CA; Griguolo G; Marra A; Randon G; Rea CG; Ligorio F; Scagnoli S; De Angelis C; Molinelli C; Fabbri A; Ferraro E; Trapani D; Milani A; Agostinetto E; Bernocchi O; Catania G; Vantaggiato A; Palleschi M; Moretti A; Basile D; Cinausero M; Ajazi A; Castagnoli L; Lo Vullo S; Gerratana L; Puglisi F; La Verde N; Arpino G; Rocca A; Ciccarese M; Pedersini R; Fabi A; Generali D; Losurdo A; Montemurro F; Curigliano G; Del Mastro L; Michelotti A; Cortesi E; Guarneri V; Pruneri G; Mariani L; de Braud F
Clin Cancer Res; 2021 Jun; 27(12):3443-3455. PubMed ID: 33785482
[TBL] [Abstract][Full Text] [Related]
34. The impact of mandatory mammographic breast density notification on supplemental screening practice in the United States: a systematic review.
Huang S; Houssami N; Brennan M; Nickel B
Breast Cancer Res Treat; 2021 May; 187(1):11-30. PubMed ID: 33774734
[TBL] [Abstract][Full Text] [Related]
35. Gut microbiome, body weight, and mammographic breast density in healthy postmenopausal women.
Yaghjyan L; Mai V; Wang X; Ukhanova M; Tagliamonte M; Martinez YC; Rich SN; Egan KM
Cancer Causes Control; 2021 Jul; 32(7):681-692. PubMed ID: 33772705
[TBL] [Abstract][Full Text] [Related]
36. Assessment of a Risk-Based Approach for Triaging Mammography Examinations During Periods of Reduced Capacity.
Miglioretti DL; Bissell MCS; Kerlikowske K; Buist DSM; Cummings SR; Henderson LM; Onega T; O'Meara ES; Rauscher GH; Sprague BL; Tosteson ANA; Wernli KJ; Lee JM; Lee CI
JAMA Netw Open; 2021 Mar; 4(3):e211974. PubMed ID: 33764423
[TBL] [Abstract][Full Text] [Related]
37. Post-diagnostic coffee and tea consumption and breast cancer survival.
Farvid MS; Spence ND; Rosner BA; Willett WC; Eliassen AH; Holmes MD
Br J Cancer; 2021 May; 124(11):1873-1881. PubMed ID: 33762714
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy of interventions for reducing symptoms of depression in people with dementia: systematic review and network meta-analysis.
Watt JA; Goodarzi Z; Veroniki AA; Nincic V; Khan PA; Ghassemi M; Lai Y; Treister V; Thompson Y; Schneider R; Tricco AC; Straus SE
BMJ; 2021 Mar; 372():n532. PubMed ID: 33762262
[TBL] [Abstract][Full Text] [Related]
39. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry.
Ibragimova KIE; Geurts SME; Croes S; Erdkamp F; Heijns JB; Tol J; Vriens BEPJ; Aaldering KNA; Dercksen MW; Pepels MJAE; Peters NAJB; van de Winkel L; Tilli DJP; Vriens IJH; de Boer M; Tjan-Heijnen VCG
Breast Cancer Res Treat; 2021 Jul; 188(2):571-581. PubMed ID: 33743103
[TBL] [Abstract][Full Text] [Related]
40. Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019.
Ma S; Guo C; Sun C; Han T; Zhang H; Qu G; Jiang Y; Zhou Q; Sun Y
Clin Breast Cancer; 2021 Dec; 21(6):552-565. PubMed ID: 33741292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
